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Abstract
OBJECTIVE: To probe insights into the reversal ef-
fect of bufalin on vincristine-acquired multidrug re-
sistance (MDR) in human leukemia cell line K562/
VCR.
METHODS: Proliferative inhibition rate and the re-
versal index (RI) of bufalin were determined by
Methyl thiazolyl tetrazolium assay. The uptake of
Adriamycin (ADM) in K562/VCR cells, cell cycle and
apoptosis rate were determined by flow cytometry
(FCM). Cell morphologic changes were observed
with Wright-Giemsa staining. The expression of
P-glycoprotein (P-gp), multidrug-associated pro-
tein-1 (MRP1), Bcl-xL and Bax protein were mea-
sured by immunocytochemistry.
RESULTS: The human leukemia multidrug resistant
K562/VCR cells showed no cross-resistance to bufa-
lin. The RIs of bufalin at concentrations of 0.0002,
0.001 and 0.005 μmol/L were 4.85, 6.94 and 14.77,
respectively. Preincubation of 0.001 μmol/L bufalin
for 2 h could increase intracellular ADM fluores-
cence intensity to 28.07% (P<0.05) and down-regu-
late MRP1 expression simultaneously, but no re-
markable effect was found on P-gp protein. Cell cy-
cle analysis indicated increased apoptosis rate and
apparent decreased G2/M phase proportion after
treatment with bufalin. When exposed to 0.01
μmol/L bufalin, typical morphological changes of
apoptosis could be observed. Down-regulation of
Bcl-xL and up-regulation of Bax expression in K562/
VCR cells could be detected by immunocytochem-
istry.
CONCLUSION: Bufalin could partly reverse the
MDR of K562/VCR cells, with a possible mechanism
of down-regulating MRP1 expression and activat-
ing apoptosis pathway by altering Bcl-xL/Bax ratio.
© 2014 JTCM. All rights reserved.
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INTRODUCTION
Chemotherapy is a primary therapy for leukemia,
while multidrug resistance (MDR) of leukemia cells to
chemotherapeutic drugs could largely compromise the
effectiveness of chemotherapy and thus becomes one of
the important causes of a therapeutic failure. MDR re-
fers to spontaneous or acquired drug resistance of tu-
mor cells to various anticancer medications of unrelat-
ed structures. Clinical application of classic multi-drug
resistance modifiers (RM) is somewhat limited due to
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serious toxicities developed when the working concen-
tration is reached. RMs among traditional Chinese
medications have caught researchers' eyes by their few-
er toxic side effects and more working targets.1 Bufalin
is a toxic ligand extracted from Chansu (Venenum Bufo-
nis) a medicinal used in Traditional Chinese Medicine
(TCM). Research has revealed a multi-target anti-tu-
mor effect of bufalin on tumor cell differentiation and
apoptosis induction, as well as related gene expression
and signal transduction.2 Studies also found that bufa-
lin could reverse the drug resistance of leukemia cells
to retinoic acid, VP-16 and other agents, but the un-
derlying mechanism is unknown.3,4 The purpose of this
study is to investigate the mechanism of bufalin possi-
bly underpinning its reversal effect on human leukemia
K562/VCR multi-drug resistant cell line and its .
METHODS
Cell culture
Human chronic myeloid leukemia cell line K562 pur-
chased from Shanghai Institute of Cell Biology (Shang-
hai, China) and human leukemia multidrug resistant
cell line K562/VCR introduced from the Institute of
Hematology, Chinese Academy of Sciences (Tianjin,
China) were cultured in RPMI-1640 complete medi-
um containing 10% fetal calf serum at 37℃ , 5% CO2
and saturated humidity.
Drugs and reagents
Ten milligram of bufalin powder (Sigma-Aldrich Co.,
Santa Clara, CA, USA) was dissolved into 200 μL of
anhydrous ethanol, and injectable water was added to
prepare a 1000 μmol/L concentration solution. Methyl
thiazolyl tetrazolium (MTT) (Amresco), RPMI-1640
medium (Gibco), fetal calf serum (Hangzhou Ever-
green Biological Corporation, Hangzhou, China), vin-
cristine (VCR, Zhejiang Haizheng Pharmaceutical
Co., Ltd., Zhejiang, China), adriamycin (ADM, Shen-
zhen Wan Yue Pharmaceutical Co., Ltd., Shenzhen,
China), multidrug resistance-associated protein-1
(MRP1), P-glycoprotein (P-gp) single monoclonal anti-
body (Fuzhou New Biotechnology Development Com-
pany, Fuzhou, China) were purchased; Bcl-xL
(SI-B6054) and Bax (SI-B8429) monoclonal antibod-
ies were products of Sigma-Aldrich Co., (Santa Clara,
CA, USA).
Reversal index calculation using the MTT method
K562 and K562/VCR cell lines were collected in the
logarithmic phase and underwent trypan blue staining
before adjusting of the cell concentration to 1×105/mL.
Each well of the 96 well culture plates was seeded with
100 μL cell solution, with a blank cell group and a
pure culture medium group as control groups; cells in
each well were treated with 10 μL of bufalin (with a
gradient of 7 consecutive concentrations, each diluted
10 times than the previous one) after culturing for 12 h
with another 6 wells for each concentration; MTT re-
agent (5 mg/mL, 10 μL for each well) was added 4 h
before termination of culture; After incubation, super-
natant in each well was disposed before adding 150 μL
Dimethyl sulfoxide (DMSO). Cells underwent oscilla-
tion in the thermostatic shaker for 10 min before spec-
trophotometry (A value) was measured using enzyme
standard analyzer, the detecting wavelength was 490 nm,
inhibition rate of cell proliferation was calculated as fol-
lows: inhibition rate=(A value of the control group-A
value of the experimental group)/(A value of the con-
trol group-A value of the background group)×100%.
Half inhibition concentration (IC50) was calculated by
mid-efficacy analysis (LOGIT method) with SPSS
11.0 for Windows (IBM, Armonk, NY, USA) in par-
ent cells and drug resistance cells.
Two hours before adding different concentrations of
VCR, bufalin of three low cytotoxic concentrations
(0.0002, 0.001, 0.005 μmol/L) were added, the rever-
sal index (RI) was calculated using the same MTT
method described above according to the following for-
mula: RI=IC50 in blank control group/IC50 in re-
versed group.
Cell uptake of adriamycin detection by flow
cytometry (FCM)
Cells were seeded in six-well plates (2 mL per well) af-
ter adjusted to a concentration of 1×105/mL. Bufalin of
different concentrations (0.001, 0.01 and 0.1 μmol/L)
was then added for 2 h following conventional culture
for 24 h. Adriamycin of a final concentration of 20 μg/
mL was added and incubated for 2 h before cold PBS
(4℃, 0.01 mol/L, pH 7.4) washing and centrifugation
for two times, immediately thereafter, cells underwent
flow cytometry analysis (receiving wavelength of 575 nm
and excitation wavelength of 488 nm), the relative fluo-
rescence intensity of adriamycin with gated cells were
analyzed by CellQuest software.(Becton, Dickinson
and Company, Franklin Lakes, NJ, USA)
FCM analysis of cell cycle and apoptosis rate
Cells treated with different concentrations of bufalin
for 48 h were collected and underwent flow cytometry
analysis of DNA content with methods same as litera-
ture reported,5 cell cycle and apoptosis rate of cells
were measured using ModFit LT for Mac V3.0 soft-
ware (Verity Software House, Topsham, ME, USA).
Cell morphology under inverted microscope
K562/VCR cells treated by 0.01 μmol/L of bufalin for
48 h were collected and living cells were observed un-
der the inverted microscope while conventional smears
of cells underwent Wright-Giemsa staining were ob-
served under light microscope (BX53, Olympus, To-
kyo, Japan).
Immunocytochemistry
K562/VCR cells treated with bufalin (0.01 μmol/L)
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for 48 h underwent conventional smears. P-gp, MRP1,
Bcl-xL and Bax were detected with immunocytochem-
istry following Envision two-step method. Cells with a
pale-brown staining of the membrane or cytoplasm
were defined as positive, quantitative analysis of the
positive expression intensity was done using the Infor-
mation Management System (IMS) computer cell im-
age analysis system. Six vision fields were randomly se-
lected under light microscope (× 100), the percentage
of positive area and mean optical density value were
calculated by default sampling procedures, the product
of the above 2 figures was defined as the positive index
(PI) of immunohistochemistry.
Statistical analysis
Statistical analysis was done with SPSS 11.0 for Win-
dows (IBM, Armonk, NY, USA), mean differences be-
tween groups were compared by t test or variance anal-
ysis, data was presented as mean standard ± deviation
(SD) and P<0.05 was significant level.
RESULTS
Reversal effect of bufalin
Cell proliferation of K562 and K562/VCR was signifi-
cantly inhibited by bufalin for 72 h, with an IC50 of
K562 parental cells and resistant K562/VCR cells
0.0943 μmol/L and 0.0401 μmol/L, respectively. In
resistant cells, proliferation inhibition rates of bufalin
with 0.0002, 0.001 and 0.005 μmol/L concentra-
tions were 7.24%, 14.51% and 23.15%, respectively.
These low-cytotoxic concentrations could partially re-
verse the resistance of the K562/VCR cells. The re-
versal indices were 4.85, 6.94 and 14.77 times (Fig-
ure 1).
Adriamycin uptake analysis
A concentration of 0.001 μmol/L enhanced the mean
fluorescence intensity of adriamycin in K562/VCR
cells approximately by 28.07% compared with the con-
trol group (P<0.05, Figure 2).
December 15, 2014 |Volume 34 | Issue 6 |
0 μmol/L 0.0002 μmol/L 0.001 μmol/L 0.005 μmol/L
1.2
1.0
0.8
0.6
0.4
0.2
0.0
0.0008 0.002 0.003 0.006 0.013 0.025 0.05
VCR (μmol/L)
Inh
ibi
tio
nr
ate
(%
)
Figure 1 Effect of bufalin on enhancing the sensitivity of K562/VCR cell line to vincristine（VCR）in vitro (n=6)
Proliferation inhibition rates of bufalin to resistant cells were 7.24% , 14.51% and 23.15% , with concentrations of 0.0002 ,
0.001 and 0.005 μmol/L respectively. These low-cytotoxic concentrations could partially reverse the resistance of the K562/
VCR cells.
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Cell cycle and apoptosis analysis
The s-phase fraction in all groups treated with differ-
ent dose of bufalin for 48 h increased significantly.
The G2/M ratio decreased with increasing drug con-
centration while the rate of apoptosis went proportion-
ally with drug concentration. The G2/M ratio was neg-
atively correlated to the cell apoptosis rate (r=﹣0.98,
P<0.05; Table 1).
Morphological changes
Before bufalin administration, K562/VCR cells had
larger nuclear, prominent nucleoli with intact cell
membranes and numerous mitotic figures. After treat-
ed by 0.01 μmol/L bufalin for 48 h, cell shrinkage,
membrane blistering, nuclear condensation and other
morphological changes were observed and became
more noticeable with higher bufalin concentrations
and longer duration of time. Some cells showed trypan
blue stain resistance, suggesting the apoptotic cell char-
acters (Figure 3).
Immune cells chemical examination
P-gp and MRP1 protein expressions were positive in
K562/VCR cell lines. Forty-eight hours after bufalin
administration, no significant change was found in
P-gp protein expression while positive index of MRP1
protein (P<0.05) and Bcl-xL protein (P<0.05) both de-
creased significantly, whereas the Bax protein positive
index was significantly elevated (P<0.05, Table 2)
DISCUSSION
Bufalin, one of the ligands extracted from Chansu
(Venenum Bufonis), is a cardiac glycoside with an an-
ti-cancer effect. This regimen inhibits topoisomerase
enzyme Ⅱ (TopoⅡ), protein kinase A and protein ki-
nase C activity as well as down-regulating casein ki-
nase-2 at low concentrations (0.001 mol/L), thereby in-
ducing cell differentiation,6 at high concentrations
(0.01 mol/L or higher) it plays selective role in leuke-
mia cells not only by inhibition of DNA synthesis and
regulation of casein kinase 2 shift, but also by adjusting
TopoⅡ activity after binding to TopoⅡ-alpha and
thereby decreasing its concentration and activity to in-
duce apoptosis in leukemic cells.7,8 The present study
discovered a powerful role of bufalin in destruction of
K562 pro-cells and significant proliferative inhibition
in human leukemia multidrug resistant K562/VCR
cell line. On the other hand, IC50 in K562 parental
cells showed no significant difference compared with
resistant cells after 72 h of bufalin, suggesting that
K562/VCR multi-drug resistant cell developed no
cross-resistance to bufalin. Incubated for 2 h with low
cytotoxic concentrations of bufalin enhanced the sensi-
tivity of K562/VCR cells to VCR. The reverse index
was concentration-dependent, indicating an in vitro re-
versal effect of bufalin on multidrug resistance.
MDR mediated by over-expression of ABC (ATP the
Note: compared with control group, aP<0.05.
Bufalin (μM)
0
0.001
0.01
0.1
Phases of cell cycle (%)
G0/G1
28.68±1.98
4.88±1.03
19.03±1.54
23.65±2.47
S
47.97±2.64
81.26±6.57a
73.19±1.45a
73.62±2.89a
G2/M
23.34±3.24
13.86±5.94a
7.77±0.35a
2.72±0.56a
Apoptosis (%)
1.72±0.25
6.53±1.02a
14.70±1.06a
18.47±0.75a
Table 1 Cell cycle arrest and apoptiosis of K562/VCR cells induced by Bufalin ( xˉ ±s)
Figure 3 Bufalin induce apoptosis of K562/VCR cells (Invert-
ed microscope, ×400)
A: before bufalin treatment, K562/VCR cells had larger nucle-
ar, prominent nucleoli with intact cell membranes and nu-
merous mitotic figures; B: K562/VCR cells incubated with Bu-
falin of 0.01 μmol/L for 48 h. Cell shrinkage, membrane blis-
tering, nuclear condensation and other morphological
changes were observed. Arrowhead indicated the cells un-
dergoing apoptosis.
A B
Figure 2 Bufalin enhance the uptake of ADM in K562/VCR
cells (n=3)
ADM: adriamycin. Bufalin can increase the concentration of
adriamycin in human leukemia multidrug resistant cells.
This effect is enhanced when treated with a lower concen-
tration of bufalin.
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binding cassette) -type membrane carrier protein family
can significantly reduce the effective intracellular con-
centration of chemotherapy drugs in leukemia cells,
which serve as the predominant reason for drug resis-
tance. Previous studies have indicated that MDR mech-
anisms of K562/VCR cell line were attributed mainly
to over-expression of cell membrane P-glycoprotein
(P-gp), which may lead to an increased intracellular an-
ticancer drug efflux and elevated glutathione-S-transfer-
ase expression, therefore further increase the detoxifica-
tion function of the cells to chemotherapeutic drugs 9
and expression of multidrug resistance associated pro-
tein (MRP).10 Some studies have found a reversal effect
of bufalin on vinblastine resistant CEM/VLB cell line
(100) and epirubicin resistant CEM/E1000 cell line, as
well as the capacity to increase the accumulation of
daunorubicin within both cell lines, 11 but further stud-
ies are yet to be reported.
Our results showed that all concentrations of bufalin
could increase the intracellular accumulation of ADM
within K562/VCR cells, interestingly, this effect was
negatively correlated with the concentration of bufalin,
concentrations with low cytotoxicity could enhance in-
tracellular adriamycin content of about 28.07% in
K562/VCR cells. In addition, immunocytochemistry
revealed a significantly lowered expression of MRP1
while no obvious effect on the expression of P-gp, sug-
gesting that enhanced intracellular chemotherapeutic
drug accumulation may be associated with lowered
MRP1 expression after bufalin administration.
Studies have shown that a variety of anticancer drugs
with different chemical structures and distinct targets
of can induce tumor cell apoptosis, while enhanced an-
ti-apoptotic effect is a common phenomenon devel-
oped in tumor cells to evade chemotherapy.12 Recent
researches have indicated the hindered apoptosis path-
way might play an important role in tumor MDR de-
velopment.13 The anti-apoptotic effects of tumor cells
are regulated by a series of apoptosis regulatory pro-
teins, such as p53, Bcl-2 family and Fas. Studies have
demonstrated that the ability of cells to resist apoptosis
enhanced with increased Bcl-xL/Bax ratio, while a low
ratio promotes apoptosis. High expression of anti-apop-
totic protein Bcl-xL is believed to be one of the mecha-
nisms of MDR development in K562/VCR cells.14
Apoptosis of K562 cells caused by DNA damage induc-
ers is mainly dependent on the Bcl-xL/Bax ratio at the
mitochondrial level, for instance, PUMA gene transfec-
tion can activate Bax to induce apoptosis of K562
cells.15 Studies have shown that bufalin can inhibit
DNA synthesis in endometriotic cyst stromal cells and
induce apoptosis, the underlying mechanism is by de-
creasing anti-apoptotic Bcl-2 and Bcl-xL and promot-
ing the activation of pro-apoptotic Bax expression, and
subsequently triggering caspase-9 cascade reaction fol-
lowed by induction of apoptosis eventually.16 The pres-
ent study also found that concentration of bufalin
above 0.01 μmol/L significantly lowered the expression
of Bcl-xL, up-regulated Bax expression and change the
Bcl-xL/Bax ratio of mitochondria-dependent apoptotic
pathway in cells with drug resistant, indicating a possi-
ble correlation between inhibited apoptosis pathway
mediated by activation of Bcl-2 and the reversal effect
of bufalin on K562/VCR cell multidrug resistance de-
velopment.
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